Page last updated: 2024-10-30

labetalol and Anti-MuSK Myasthenia Gravis

labetalol has been researched along with Anti-MuSK Myasthenia Gravis in 2 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hamaoui, A1
Mercado, R1
Leys, D1
Pasquier, F1
Vermersch, P1
Gosset, D1
Michiels, H1
Kassiotis, P1
Petit, H1

Other Studies

2 other studies available for labetalol and Anti-MuSK Myasthenia Gravis

ArticleYear
Association of preeclampsia and myasthenia: a case report.
    The Journal of reproductive medicine, 2009, Volume: 54, Issue:9

    Topics: Antihypertensive Agents; Cesarean Section; Cholinesterase Inhibitors; Female; HELLP Syndrome; Humans

2009
Possible revelation of latent myasthenia gravis by labetalol chlorhydrate.
    Acta clinica Belgica, 1987, Volume: 42, Issue:6

    Topics: Female; Humans; Hypertension; Labetalol; Middle Aged; Myasthenia Gravis

1987